ES2655091T3 - Derivados del ácido pirrolidíncarboxílico como agonistas del receptor 43 acoplado a proteína G (GPR43), composición farmacéutica y métodos para su uso en el tratamiento de trastornos metabólicos - Google Patents
Derivados del ácido pirrolidíncarboxílico como agonistas del receptor 43 acoplado a proteína G (GPR43), composición farmacéutica y métodos para su uso en el tratamiento de trastornos metabólicos Download PDFInfo
- Publication number
- ES2655091T3 ES2655091T3 ES10792934T ES10792934T ES2655091T3 ES 2655091 T3 ES2655091 T3 ES 2655091T3 ES 10792934 T ES10792934 T ES 10792934T ES 10792934 T ES10792934 T ES 10792934T ES 2655091 T3 ES2655091 T3 ES 2655091T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- aryl
- heteroaryl
- group
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102100040133 Free fatty acid receptor 2 Human genes 0.000 title 2
- 101710142059 Free fatty acid receptor 2 Proteins 0.000 title 2
- 239000000556 agonist Substances 0.000 title 1
- 208000030159 metabolic disease Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical class OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 title 1
- -1 hydroxycarbamoyl Chemical group 0.000 abstract 10
- 125000003118 aryl group Chemical group 0.000 abstract 9
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 7
- 125000001072 heteroaryl group Chemical group 0.000 abstract 7
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 6
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 5
- 125000001424 substituent group Chemical group 0.000 abstract 5
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000001188 haloalkyl group Chemical group 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 3
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 abstract 3
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 abstract 3
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 abstract 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 2
- 125000005083 alkoxyalkoxy group Chemical group 0.000 abstract 2
- 125000003282 alkyl amino group Chemical group 0.000 abstract 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 2
- 125000005530 alkylenedioxy group Chemical group 0.000 abstract 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 2
- 125000004441 haloalkylsulfonyl group Chemical group 0.000 abstract 2
- 125000004664 haloalkylsulfonylamino group Chemical group 0.000 abstract 2
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- XKTYXVDYIKIYJP-UHFFFAOYSA-N 3h-dioxole Chemical compound C1OOC=C1 XKTYXVDYIKIYJP-UHFFFAOYSA-N 0.000 abstract 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 abstract 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 abstract 1
- 125000005115 alkyl carbamoyl group Chemical group 0.000 abstract 1
- 125000005153 alkyl sulfamoyl group Chemical group 0.000 abstract 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 abstract 1
- 125000005116 aryl carbamoyl group Chemical group 0.000 abstract 1
- 125000005199 aryl carbonyloxy group Chemical group 0.000 abstract 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 abstract 1
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 abstract 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 abstract 1
- 125000005144 cycloalkylsulfonyl group Chemical group 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000005221 halo alkyl carbonyl amino group Chemical group 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 125000005204 heteroarylcarbonyloxy group Chemical group 0.000 abstract 1
- 125000005226 heteroaryloxycarbonyl group Chemical group 0.000 abstract 1
- 125000005419 heteroarylsulfonylamino group Chemical group 0.000 abstract 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 125000006413 ring segment Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09306270 | 2009-12-18 | ||
| US37337010P | 2010-08-13 | 2010-08-13 | |
| US37601310P | 2010-08-23 | 2010-08-23 | |
| PCT/EP2010/070040 WO2011073376A1 (en) | 2009-12-18 | 2010-12-17 | Pyrrolidine or thiazolidine carboxylic acid derivatives, pharmaceutical composition and methods for use in treating metabolic disordersas as agonists of g- protein coupled receptor 43 (gpr43) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2655091T3 true ES2655091T3 (es) | 2018-02-16 |
Family
ID=42236460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10792934T Active ES2655091T3 (es) | 2009-12-18 | 2010-12-17 | Derivados del ácido pirrolidíncarboxílico como agonistas del receptor 43 acoplado a proteína G (GPR43), composición farmacéutica y métodos para su uso en el tratamiento de trastornos metabólicos |
Country Status (23)
| Country | Link |
|---|---|
| US (6) | US9695120B2 (enExample) |
| EP (2) | EP2513053B1 (enExample) |
| JP (1) | JP6144913B2 (enExample) |
| KR (1) | KR101827529B1 (enExample) |
| CN (1) | CN102812003B (enExample) |
| AU (1) | AU2010332765C1 (enExample) |
| BR (1) | BR112012018374B1 (enExample) |
| CA (1) | CA2784528C (enExample) |
| CY (1) | CY1119730T1 (enExample) |
| DK (1) | DK2513053T3 (enExample) |
| EA (1) | EA023861B3 (enExample) |
| ES (1) | ES2655091T3 (enExample) |
| HR (1) | HRP20171991T1 (enExample) |
| HU (1) | HUE038064T2 (enExample) |
| LT (1) | LT2513053T (enExample) |
| MX (1) | MX339252B (enExample) |
| NO (1) | NO2513053T3 (enExample) |
| PL (1) | PL2513053T3 (enExample) |
| PT (1) | PT2513053T (enExample) |
| RS (1) | RS56751B1 (enExample) |
| SI (1) | SI2513053T1 (enExample) |
| SM (1) | SMT201800004T1 (enExample) |
| WO (1) | WO2011073376A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2513053T3 (enExample) * | 2009-12-18 | 2018-03-03 | ||
| NZ626973A (en) * | 2012-01-06 | 2016-09-30 | Novartis Ag | Heterocyclic compounds and methods for their use |
| JP2015522080A (ja) | 2012-07-11 | 2015-08-03 | エルセリクス セラピューティクス インコーポレイテッド | スタチン、ビグアナイド、およびさらなる薬剤を含む心血管代謝性リスクを減少させるための組成物 |
| AR094929A1 (es) | 2013-02-28 | 2015-09-09 | Bristol Myers Squibb Co | Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2 |
| US9828345B2 (en) | 2013-02-28 | 2017-11-28 | Bristol-Myers Squibb Company | Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors |
| DK3074008T3 (da) * | 2013-11-27 | 2019-10-21 | Epics Therapeutics | Forbindelser, farmaceutisk sammensætning og fremgangsmåder til anvendelse i behandling af inflammation |
| CN107108581B (zh) * | 2014-08-21 | 2020-06-23 | 百时美施贵宝公司 | 作为强效rock抑制剂的回接苯甲酰胺衍生物 |
| KR101656662B1 (ko) | 2014-11-18 | 2016-09-12 | 한국생명공학연구원 | 2-옥소-1,2,3,4-테트라하이드로피리미딘-5-카르복사미드 유도체를 유효성분으로 함유하는 대사성 질환 예방 또는 치료용 약학적 조성물 |
| CN107033015B (zh) * | 2017-06-02 | 2019-04-30 | 南京欧信医药技术有限公司 | 一种药物中间体的合成方法 |
| TWI796596B (zh) | 2018-02-13 | 2023-03-21 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| KR102591947B1 (ko) | 2018-04-19 | 2023-10-25 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| MX2021000100A (es) | 2018-07-13 | 2021-03-25 | Gilead Sciences Inc | Inhibidores de muerte programada-1 (pd-1)/ ligando de muerte programada 1 (pd-l1). |
| JP7158577B2 (ja) | 2018-10-24 | 2022-10-21 | ギリアード サイエンシーズ， インコーポレイテッド | Ｐｄ－１／ｐｄ－ｌ１阻害剤 |
| KR20210145787A (ko) | 2019-04-02 | 2021-12-02 | 알리고스 테라퓨틱스 인코포레이티드 | Prmt5를 표적으로 하는 화합물 |
| WO2021018786A1 (en) | 2019-07-26 | 2021-02-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of ffar2 agonists for the treatment of bacterial superinfections post-viral infection |
| CN110981779B (zh) * | 2019-11-23 | 2021-02-26 | 武汉理工大学 | R-2-(2,5-二氟苯基)吡咯烷的合成方法 |
| US12528769B2 (en) | 2020-06-10 | 2026-01-20 | Epics Therapeutics | Synthesis of (2S,5R)-5-(2-chlorophenyl)-1-(2′-methoxy-[1,1′-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid |
| JP2023540344A (ja) | 2020-09-03 | 2023-09-22 | センテッサ ファーマシューティカルズ （オレキシア） リミテッド | 二環式複素環誘導体およびオレキシン－２受容体アゴニストとしてのそれらの使用 |
| CN120077024A (zh) | 2022-10-11 | 2025-05-30 | 艾匹克治疗公司 | (2s,5r)-5-(2-氯苯基)-1-(2'-甲氧基-[1,1'-联苯]-4-羰基)吡咯烷-2-羧酸的多晶型物及其制备方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3542788A (en) | 1968-06-12 | 1970-11-24 | Searle & Co | 1-amino-5-phenyl-2-pyrrolepropionic acid and congeners |
| US4006075A (en) | 1975-01-06 | 1977-02-01 | Exxon Research And Engineering Company | Method of regenerating a cracking catalyst with substantially complete combustion of carbon monoxide |
| DE3421295A1 (de) | 1984-06-08 | 1985-12-12 | Basf Ag, 6700 Ludwigshafen | Neue pyrrolidincarbonsaeurederivative, verfahren zu ihrer herstellung |
| JPH06104658B2 (ja) * | 1988-06-23 | 1994-12-21 | 三菱化成株式会社 | ピロールカルボン酸誘導体 |
| FR2678938B1 (fr) * | 1991-07-10 | 1993-10-08 | Rhone Poulenc Rorer Sa | Derives de pyrrolidine, leur preparation et les medicaments les contenant. |
| GB9206757D0 (en) | 1992-03-27 | 1992-05-13 | Ferring Bv | Novel peptide receptor ligands |
| AU1856997A (en) | 1996-02-02 | 1997-08-22 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| JP3005469B2 (ja) | 1996-06-05 | 2000-01-31 | 住友軽金属工業株式会社 | 内面スズめっき長尺銅管の製造方法 |
| US6177464B1 (en) | 1997-03-14 | 2001-01-23 | Sepracor, Inc. | Ring opening metathesis of alkenes |
| WO2001085720A1 (en) | 2000-05-05 | 2001-11-15 | Smithkline Beecham Corporation | Novel anti-infectives |
| US7105556B2 (en) * | 2001-05-30 | 2006-09-12 | Bristol-Myers Squibb Company | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
| EP1440069B1 (en) | 2001-11-02 | 2007-08-15 | Glaxo Group Limited | 4-(6-membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors |
| FI20030014A0 (fi) * | 2003-01-03 | 2003-01-03 | Orion Corp | Prolyylioligopeptidaasia inhiboivaa aktiivisuutta omaavia yhdisteitä |
| US20040142379A1 (en) * | 2003-01-16 | 2004-07-22 | Carlsberg Research Laboratory | Affinity fishing for ligands and proteins receptors |
| US7459472B2 (en) * | 2003-08-08 | 2008-12-02 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
| AU2004263508A1 (en) | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
| TW200528107A (en) * | 2003-11-25 | 2005-09-01 | Nissan Chemical Ind Ltd | T-type calcium channel inhibitor |
| WO2005122379A2 (en) * | 2004-05-27 | 2005-12-22 | The Regents Of The University Of California | Alpha-4 beta-1 integrin ligands for imaging and therapy |
| SG155896A1 (en) | 2004-09-22 | 2009-10-29 | Arena Pharm Inc | Gpr43 and modulators thereof for the treatment of metabolic-related disorders |
| US7759337B2 (en) | 2005-03-03 | 2010-07-20 | Amgen Inc. | Phthalazine compounds and methods of use |
| US7425633B2 (en) * | 2005-08-26 | 2008-09-16 | National Health Research Institutes | Pyrrolidine compounds |
| US8202902B2 (en) * | 2006-05-05 | 2012-06-19 | The Regents Of The University Of Michigan | Bivalent SMAC mimetics and the uses thereof |
| US20090004140A1 (en) * | 2007-06-26 | 2009-01-01 | Yao-Ling Qiu | 4-substituted pyrrolidine as anti-infectives |
| US20090233972A1 (en) | 2008-03-12 | 2009-09-17 | Yat Sun Or | Substituted heterocycles as anti-infectives |
| US20100074863A1 (en) | 2008-09-17 | 2010-03-25 | Yat Sun Or | Anti-infective pyrrolidine derivatives and analogs |
| NO2513053T3 (enExample) * | 2009-12-18 | 2018-03-03 |
-
2010
- 2010-12-17 NO NO10792934A patent/NO2513053T3/no unknown
- 2010-12-17 WO PCT/EP2010/070040 patent/WO2011073376A1/en not_active Ceased
- 2010-12-17 EP EP10792934.1A patent/EP2513053B1/en active Active
- 2010-12-17 HU HUE10792934A patent/HUE038064T2/hu unknown
- 2010-12-17 ES ES10792934T patent/ES2655091T3/es active Active
- 2010-12-17 CN CN201080064345.3A patent/CN102812003B/zh active Active
- 2010-12-17 BR BR112012018374-5A patent/BR112012018374B1/pt active IP Right Grant
- 2010-12-17 RS RS20171317A patent/RS56751B1/sr unknown
- 2010-12-17 LT LTEP10792934.1T patent/LT2513053T/lt unknown
- 2010-12-17 EA EA201200918A patent/EA023861B3/ru active IP Right Maintenance
- 2010-12-17 MX MX2012007030A patent/MX339252B/es active IP Right Grant
- 2010-12-17 HR HRP20171991TT patent/HRP20171991T1/hr unknown
- 2010-12-17 EP EP17175370.0A patent/EP3255038A1/en not_active Withdrawn
- 2010-12-17 SM SM20180004T patent/SMT201800004T1/it unknown
- 2010-12-17 SI SI201031607T patent/SI2513053T1/en unknown
- 2010-12-17 CA CA2784528A patent/CA2784528C/en active Active
- 2010-12-17 KR KR1020127018966A patent/KR101827529B1/ko active Active
- 2010-12-17 DK DK10792934.1T patent/DK2513053T3/en active
- 2010-12-17 PL PL10792934T patent/PL2513053T3/pl unknown
- 2010-12-17 PT PT107929341T patent/PT2513053T/pt unknown
- 2010-12-17 AU AU2010332765A patent/AU2010332765C1/en active Active
- 2010-12-17 JP JP2012543780A patent/JP6144913B2/ja active Active
-
2012
- 2012-06-18 US US13/526,337 patent/US9695120B2/en active Active
-
2017
- 2017-06-15 US US15/624,290 patent/US10017468B2/en active Active
-
2018
- 2018-01-04 CY CY20181100010T patent/CY1119730T1/el unknown
- 2018-06-20 US US16/013,281 patent/US10358416B2/en active Active
-
2019
- 2019-06-18 US US16/444,781 patent/US10577318B2/en active Active
-
2020
- 2020-01-17 US US16/745,727 patent/US10781171B2/en active Active
- 2020-07-15 US US16/929,573 patent/US11072582B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2655091T3 (es) | Derivados del ácido pirrolidíncarboxílico como agonistas del receptor 43 acoplado a proteína G (GPR43), composición farmacéutica y métodos para su uso en el tratamiento de trastornos metabólicos | |
| CR20220371A (es) | Agonistas heterocíclicos de glp-1 | |
| AR060545A1 (es) | Compuestos de benzoaxol y benzotiazol 6-0- sustituidos y metodos de inhibicion de la senalizacion de csf-1r. composiciones farmaceuticas | |
| AR055076A1 (es) | Derivados de1,1-dioxido de 1,4-benzotiazepina,procedimiento para prepararlos,composiciones farmaceuticas que los contienen y usos en terapeutica. | |
| AR073209A1 (es) | Tienopirimidinas utiles para la profilaxis y/o tratamiento de enfermedades influenciadas por la inhibicion de quinasas mnk1 y/o mnk2 ,tales como enfermedades metabolicas y trastornos inflamatorios,y composiciones farmaceuticas que las contienen. | |
| AR066882A1 (es) | Derivados de oxadiazol, una composicion farmaceutica que los comprende y su uso en la preparacion de medicamentos para el tratamiento de trastornos asociados con la disfuncion del glutamato. | |
| BRPI0608732A2 (pt) | composto ou um sal, hidrato, solvato, complexo ou pró-droga farmaceuticamente aceitável do mesmo, sal de um composto, processo para a preparação de um composto, uso de um composto, composição farmacêutica, e, produto | |
| AR072085A1 (es) | Compuestos triciclicos, metodos para su preparacion, composicion farma-ceutica que los comprende y su uso en el tratamiento de enfermedades me-diadas por la actividad de las proteinas quinasas | |
| PE20180227A1 (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
| CO6170361A2 (es) | Composiciones y metodos para modular receptores de c-kit y pdgfr | |
| AR065806A1 (es) | Derivados de quinolina, procesos para su preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de la artritis reumatoidea. | |
| AR086254A1 (es) | Derivados de imidazol utiles para el tratamiento de artritis | |
| MX2021013135A (es) | Derivados de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2. | |
| AR049398A1 (es) | Derivados de sulfamato y sulfamida; una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento util para el tratamiento de la epilepsia y trastornos relacionados. | |
| PE20091425A1 (es) | Derivados de aminotiazol | |
| HRP20210847T1 (hr) | Supstituirani derivati indola kao inhibitori replikacije denga virusa | |
| EA201891780A1 (ru) | Производные сульфонамида и содержащие их фармацевтические композиции | |
| AR072803A1 (es) | Tetrahidrocinolinas como inhibidores de la 11- beta -hsd1 para la diabetes | |
| AR068115A1 (es) | Derivado del acido pirazolcarboxilico metodo de produccion del mismo y fungicida | |
| HRP20080052T3 (hr) | Derivati tropana supstituirani imidazopiridinom santagonističkim djelovanjem na ccr5 receptor za liječenje hiv-a i upala | |
| AR109224A2 (es) | Formas de sales cristalinas de un compuesto 8-azabiciclo[3,2,1]octano, composición farmacéutica que las comprende, procesos para prepararlas, compuesto intermediario de síntesis relacionado y su uso para la fabricación de un medicamento | |
| RU2017117559A (ru) | Бензопроизводные с шестичленным кольцом в качестве ингибитора dpp-4 и их применение | |
| UY30851A1 (es) | Proceso para la sintesis de derivados de acido 3-amino-tetrahidrofuran-3-carboxilico y uso de los mismos como medicamentos | |
| RU2010115337A (ru) | Трициклические гетероциклические производные | |
| RU2009102270A (ru) | Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы |